WRAIR and collaborators will share data related to assays designed to measure antibody
responses following vaccination with ZPIV, biologic samples generated during the performance of animal studies, and biologic samples generated during the performance of early human trials assessing the safety and immunogenicity of ZPIV.
In addition, he is interested in understanding the effect that adjuvants have on the generation and maturation of antiviral antibodies, and is working to develop a number of high - throughput techniques for evaluation of complex antibody
responses following vaccination in animals and humans.
Identification of optimal vaccine formulations and administration routes for the induction of CD8 + T - cell responses (SSI): The induction of suitable CD8 + T - cell
responses following vaccination usually requires the use of live viral vectors.
Kim et al. suggest that moving away from empirical research to either systems analysis or hypothesis driven approaches may advance our vaccinology understanding.5 Interrogation of peripheral blood
responses following vaccination, termed «systems vaccinology», has led to the identification of immune signatures and pathways that are correlated to immune responses.
Feral cats appeared to have an excellent immune
response following vaccination at the time of neutering.
Recent studies have alleviated these concerns by demonstrating that cats do develop a strong immune
response following vaccination at the time of spay / neuter.
Not exact matches
Breastfeeding consistently reduced behavioural
responses of cry duration and composite pain scores during and
following vaccinations.
Researchers used the immune suppressing drug rapamycin to shift the immune
response following flu
vaccination to favor production of antibodies that broadly target flu viruses.
They found substantial differences
following influenza
vaccination in the production of immune - modulators that determine the type of T - cell
response and in the proliferation and production of antibodies by B cells.
Further analysis showed that the improved antibody
response following AMA1 - RON2
vaccination was due to an increased proportion of antibodies aimed directly at the AMA1 - RON2 junction, which made them better at inhibiting parasite invasion.
In contrast, similar ASC
responses were not detected
following the second dose of
vaccination.
The HZI will develop a
vaccination protocol for mucosal administration based on three novel strategies: (i) development and optimization of a
vaccination protocol in which parenterally - primed T and B cells are subsequently pulled into the mucosa by the local delivery of the cognate antigen to the requested effector site, (ii) testing the co-administration of antigens with novel mucosal adjuvants using different mucosal immunisation routes and schedules, and (iii) testing various nanoparticles co-administered with different immunomodulators for their ability to generate both systemic and mucosal immune
responses following transcutaneous / trans - follicular
vaccination.
(iii) Test various nanoparticles co-administered with different immunomodulators for their ability to generate both systemic and mucosal immune
responses following transcutaneous / trans - follicular
vaccination.
The development of anti-galectin 3 polyclonal
responses in pancreatic cancer patients after
vaccination with GVAX (2) or prostate cancer patients
following Sipuleucel - T (3) has been associated to prolonged survival, thus providing an supportive rationale for targeting galectin 3.
Working with Dr. Weiskopf, we established a model of human dengue disease using HLA transgenic mouse strains, and characterized human dengue - specific CD8 + and CD4 + T - cell
responses in natural infection as well as
following vaccination.
The latter work addresses questions including whether infection with different serotypes is associated with distinct types of T cell
responses, whether any HLA alleles are associated with pathogenesis or protection, and whether
vaccination with a formulation in clinical trials is associated with T cell
responses similar to those
following infection that might serve as correlates of protection.
Broad heparin - binding haemagglutinin - specific cytokine and chemokine
response in infants
following Mycobacterium bovis BCG
vaccination.
Post-Infection Cellular Immune
Responses in Recipients
Following ALVAC - HIV ® + AIDSVAX ® B / E Prime - boost
Vaccination in the Thai Phase III Trial
Vaccination can provide an immune
response that's comparable in length to that
following a pure an infection.
Conclusions and Clinical Relevance — Results indicated that dogs with out - of - date
vaccination status were not inferior in their antibody
response following booster rabies
vaccination, compared with dogs with current
vaccination status.
This is because the second
vaccination will produce a much greater (logarithmically greater)
response if it is
following a vaccine given 2 - 4 weeks prior.